ReviewInfection and drug resistance2019
Bezlotoxumab for the prevention of
Review in Infection and drug resistance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Evaluation of the antibacterial activity of the natural product α-mangostin against Clostridioides difficile.PloS one · 2026Article
- Reviewing theMicroorganisms · 2024Review
- Immunization Strategies Against Clostridioides difficile.Advances in experimental medicine and biology · 2024Review
- A dual-action antibiotic that killsProceedings of the National Academy of Sciences of the United States of America · 2023Article
- A systematic review of real-world healthcare resource use and costs ofAntimicrobial stewardship & healthcare epidemiology : ASHE · 2023Article
- Using next generation antimicrobials to target the mechanisms of infection.npj antimicrobials and resistance · 2023Review
- The Role of Bezlotoxumab for the Prevention of RecurrentAntibiotics (Basel, Switzerland) · 2022Review
- The Efficacy of Bezlotoxumab in the Prevention of Recurrent Clostridium difficile: A Systematic Review.Cureus · 2022Review
- Microbial Resistance to Antibiotics and Effective Antibiotherapy.Biomedicines · 2022Review
- Application of recombinant antibodies for treatment ofFrontiers in immunology · 2022Review
- Antimicrobial Resistance in the COVID-19 Landscape: Is There an Opportunity for Anti-Infective Antibodies and Antimicrobial Peptides?Frontiers in immunology · 2022Review
- The Case against Antibiotics and for Anti-Virulence Therapeutics.Microorganisms · 2021Review
- Hospital outcomes and early readmission for the most common gastrointestinal and liver diseases in the United States: Implications for healthcare delivery.World journal of gastrointestinal surgery · 2021Article
- Editorial for the Special Issue:Microorganisms · 2021Article
- Real-World Experience with Bezlotoxumab for Prevention of Recurrence ofJournal of clinical medicine · 2020Article
- Risk Factors Associated with RecurrentHealthcare (Basel, Switzerland) · 2020Article
- Porcine Colostrum Protects the IPEC-J2 Cells and Piglet Colon Epithelium againstMicroorganisms · 2020Article
- The Strategies of Pathogen-Oriented Therapy on Circumventing Antimicrobial Resistance.Research (Washington, D.C.) · 2020Review
- Recent advances in the treatment ofFaculty reviews · 2020Review
- Investigational Treatment Agents for RecurrentJournal of experimental pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.